[Skip to Content]
[Skip to Content Landing]
Views 139
Citations 0
Comment & Response
October 23/30, 2018

Defining Value-Based Pricing of Drugs—Reply

Author Affiliations
  • 1Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York
JAMA. 2018;320(16):1710-1711. doi:10.1001/jama.2018.11820

In Reply Dr Broder and Mr Ortendahl critique our definition of value-based pricing as relying on cost-effectiveness analyses from ICER. That is not correct; we only mentioned the work of ICER as an example of a value-based price. They also suggest that we argued for the use of cost-effectiveness analyses and QALYs as the only measure of benefit. We did not say that, nor, to our knowledge, does ICER. Moreover, our work on tools such as the DrugAbacus explicitly acknowledges the multidimensional nature of value assessment, considering, for example, rarity of disease, unmet need, and prognosis.1